Odyssean LLC’s Arcturus Therapeutics ARCT Stock Holding History

Odyssean LLC’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,956	Closed	-$177K	–	491
2026 Q1	$177K	Buy	+22,956	New	+$168K	0.06%	382

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Odyssean LLC's ARCT Position: Q2 2026 in Review

Odyssean LLC sold out of Arcturus Therapeutics (ARCT) in Q2 2026, closing a stake of 22,956 shares — an estimated $177K sold.

Odyssean LLC first reported a position in ARCT in Q1 2026 and held it in 1 quarter. The position peaked at $177K in Q1 2026. 133 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Odyssean LLC reported no remaining Arcturus Therapeutics position as of Q2 2026 after selling out during the quarter.
Odyssean LLC sold 22,956 Arcturus Therapeutics shares in Q2 2026, an estimated $177K.
Odyssean LLC first reported a position in Arcturus Therapeutics in Q1 2026 and held it in 1 quarter.
Odyssean LLC's Arcturus Therapeutics position peaked at $177K in Q1 2026.
133 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Odyssean LLC's 13F filing for Q2 2026, filed 14 Aug 2026.